Latest hypoglycemia Stories
PHILADELPHIA, Aug. 9, 2011 /PRNewswire/ -- Echo Therapeutics, Inc.
Research published in The Cochrane Library found that the risk of death and cardiovascular disease, such as stroke, was unchanged whether glucose control was intense or conventional.
Doctors should be cautious about prescribing intensive glucose lowering treatment for patients with type 2 diabetes as a way of reducing heart complications, concludes a new study published on bmj.com today.
CALGARY, Alberta, July 27, 2011 /PRNewswire/ -- Fero Industries, Inc. (OTCQB: FROI) (the "Company") is pleased to report that Merck S.A. de C.V. has increased its SucanonÂ® promotional campaign across Mexico to include physician distributed sample packages.
JDRF says Pending Artificial Pancreas Guidance is FDA's Opportunity to Turn the Tide NEW YORK, July 20, 2011 /PRNewswire-USNewswire/ -- The Juvenile Diabetes Research Foundation (JDRF) welcomed Congress's attention today to the important issue of medical device regulatory reform and reiterated the life-changing difference the FDA's pending artificial pancreas guidance will make in the lives of millions of individuals with type 1 diabetes across the country.
Whether patients with type 2 diabetes mellitus benefit from attempts to lower their blood glucose levels to near-normal levels through treatment ("intensive blood glucose controlâ€) remains an unanswered question.
WORCESTER, Mass. and TORONTO, July 8, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTC Bulletin Board: GNBT) (www.generex.com) today announced preliminary clinical results of two major trials using the Generex Oral-lyn(TM) formulation that will be used for registration and marketing.
ORLANDO, Fla., July 7, 2011 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, and the advocacy organization Children with Diabetes, Inc.
DEERFIELD, Ill. and OSAKA, Japan, June 28, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) announced today that results from late breaking data presented by Takeda Global Research & Development Center, Inc.
SAN DIEGO, June 27, 2011 /PRNewswire/ -- Ultra-long acting insulin degludec, under development by Novo Nordisk, lowers blood glucose levels with significantly reduced rates of hypoglycemia (low blood sugar) compared to insulin glargine, according to data presented at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego.
Insulin, a hormone, is used to regulate carbohydrate and fat metabolism in the body. Insulin causes cells to take up glucose from the blood and store it as glycogen in the liver and muscle. This hormone stops the body from using fat as an energy source by inhibiting the release of glucagons. Without insulin the body fails to take glucose into the bodies cells and in turns uses fat as an energy source. It also has several other anabolic effects throughout the body. Diabetes mellitus results...
- A handkerchief.
- Specifically— The legendary sweat-cloth; the handkerchief of St. Veronica, according to tradition miraculously impressed with the mask of Christ; also, the napkin about Christ's head (Johu xx. 7).
- In general, any miraculous portrait of Christ.